Isoniazid Preventive Therapy Implementation among People Living with HIV/AIDS Enrolled in Care at Specialist Hospital Yola, Nigeria

Download Article

DOI: 10.21522/TIJPH.2013.05.04.Art022

Authors : Kabiru Usman Suru, J E Chiegil, O F Martins, S O Adeyemi



Background: Nigeria ranks 5th among the 22 countries that contributed 80% of the global Tuberculosis (TB) burden. The risk of developing TB is between 20 and 37 times greater in people living with HIV (PLWHIV) than among those who do not have HIV infection. The purpose of this study was to assess the level of Isoniazid Preventive Therapy (IPT) implementation among PLWHIV.

Methods: Retrospective cohort study conducted to examine the IPT implementation among the PLWHIV in Specialist Hospital Yola, Nigeria. Information’s were extracted from the IPT enrolment register and client’s folders, analyzed with excel and compared with the data in the District Health Information System (DHIS). Chi-square test was used to measure the strength of associations between the various variables and probability of statistical significant level set < 0.05 at 95% Confidence interval

Results: Eight hundred and seventy-three (873) clients were enrolled in to HIV care and treatment from January-December 2015 and were all screened for TB. 777 (89%) clients had no presumptive TB, only 273 (35%) clients were initiated on IPT out of those without presumptive TB. 143 (93%) clients on ART completed their IPT as against the 97 (80%) Pre-ART clients that completed IPT.

Conclusion: The IPT utilization in the prevention of TB among the PLWHIV in this health facility was very low, however consistent availability of Isoniazid and effective adherence counselling to eligible PLWHIV before commencement of IPT would help in increasing uptake and reducing the rate of defaulters on IPT.

Keywords: Tuberculosis, Implementation, Isoniazid Preventive Therapy, PLWHIV, Nigeria.


[1].     Assebe L F, Hailemariam L R, Alem D W, Wondwossen T L and Saba M L. (2015). The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: A retrospective cohort study. BMC Public Health. 15:346. DOI 10.1186/s12889-015-1719-0.

[2].     Briggs MA et al. (2015) Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature Journal of Acquired Immune Deficiency Syndrome; 68 Suppl 3:S297-305.

[3].     Chehab J.C, Vilakazi-Nhlapo K, Vranken P, Peters A, Klausner J D. (2011). Implementation of Isoniazid Preventive Therapy (IPT) in South Africa, 2011.

[4].     Durovni et al. (2011). The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) Study AIDS. Author manuscript; available in PMC 2011 March 29.

[5].     Denegetu and Dolamo (2014). Tuberculosis case finding and isoniazid preventive therapy among people living with HIV at public health facilities of Addis Ababa, Ethiopia: BMC Public Health 2014, 14:52.

[6].     Federal Ministry of Health (FMOH) Department of Public Health. Guidelines for Clinical Management of TB/HIV related conditions In Nigeria 2nd edition, 2008.

[7].     Granich, R, Akolo, C, Gunneberg, C, Getahun, H, Williams, P and Williams, B. 2010. Prevention of Tuberculosis in People Living with HIV. Clinical Infectious Diseases 50 (Suppl 3):S215–S222.

[8].     Howard and El-Sadr. (2010). Integration of Tuberculosis and HIV Services in Sub-Saharan Africa: Lessons Learned. Clinical Infectious Diseases 2010; 50(S3):S238–S244.

[9].     Melissa A. B, Courtney E, Surbhi M, Nicholas K T, et al. (2015). Use of Isoniazid Preventive Therapy for Tuberculosis Prophylaxis among People Living With HIV/AIDS. Journal of Acquired Immune Deficiency Syndromes; 68: S297–S305.

[10].  Margaret Olabisi Araoye. 2004. Research Methodology with statistics for health and social sciences. page 117-120.

[11].  Namuwenge PM, et al. (2011). Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans R Soc Trop Med Hyg (2011), doi:10.1016/j.trstmh.2011.10.015.

[12].  Nwokeukwu H I, Okorie O, Emma-U U, Ukegbu A, Nwogu K1, Ajuogu E1, Osunkwo D, Asinobi A. (2015). Use of Isoniazid Preventive Therapy on HIV/AIDS Patient in a Tertiary Health Facility South Eastern Nigeria. Science Journal of Public Health 2015; 3(2): 265-268 ( doi: 10.11648/j.sjph.20150302.26.

[13].  The Global Fund to Fight AIDS, TB and Malaria (GFATM): Collaborative TB/HIV activities information Note. (accessed 21 October 2012).

[14].  United Nations for AIDS Program (UNAIDS): Global Fund Information Note: TB/HIV Collaborative Activities. TBHIV Collaborative Activities (accessed 2 January 2013).

[15].  World Health Organization. Global tuberculosis report 2015. Geneva, Switzerland: WHO; 2015. WHO/HTM/TB/2015.22. Accessed June 2016.

[16].  World Health Organization. 2007. Treatment of TB: guideline for national programmers. 3rd edition. World Health Organization, Geneva. WHO press.

[17].  World Health Organization (WHO). Guidelines for Intensified Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings. Geneva, Switzerland: WHO; 2011.

[18].  World Health Organization (WHO). Global tuberculosis report 2013. Geneva, Switzerland: WHO; Oct 2013.

[19].  World Health Organization (WHO): Global Tuberculosis Control. 2011, (accessed 31 December 2012), Report Google Scholar.